Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $64.1 million.

  • BeOne Medicines' Other Non-Current Liabilities rose 2667.3% to $64.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.1 million, marking a year-over-year increase of 2667.3%. This contributed to the annual value of $66.7 million for FY2024, which is 3134.23% up from last year.
  • BeOne Medicines' Other Non-Current Liabilities amounted to $64.1 million in Q3 2025, which was up 2667.3% from $63.1 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Other Non-Current Liabilities registered a high of $180.5 million during Q4 2022, and its lowest value of $42.0 million during Q3 2023.
  • Its 5-year average for Other Non-Current Liabilities is $59.9 million, with a median of $51.8 million in 2022.
  • Per our database at Business Quant, BeOne Medicines' Other Non-Current Liabilities soared by 23276.54% in 2022 and then plummeted by 7184.6% in 2023.
  • Quarter analysis of 5 years shows BeOne Medicines' Other Non-Current Liabilities stood at $54.2 million in 2021, then surged by 232.77% to $180.5 million in 2022, then crashed by 71.85% to $50.8 million in 2023, then soared by 31.34% to $66.7 million in 2024, then dropped by 4.01% to $64.1 million in 2025.
  • Its last three reported values are $64.1 million in Q3 2025, $63.1 million for Q2 2025, and $65.6 million during Q1 2025.